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Available online 8 April 2019Background:Acromegaly is produced by excess growthhormone secreted by a pituitary adenomaof somatotroph
cells (ACRO). First-line therapy, surgery and adjuvant therapy with somatostatin analogs, fails in 25% of patients.
There is no predictive factor of resistance to therapy. New therapies are investigated using few dispersed tumor
cells in acute primary cultures in standard conditions where the cells do not grow, or using rat pituitary cell lines
that do not maintain the full somatotroph phenotype. The RET/PIT1/p14ARF/p53 pathway regulates apoptosis in
normal pituitary somatotrophs whereas the RET/GDNF pathway regulates survival, controlling PIT1 levels and
blocking p14ARF (ARF) and p53 expression.
Methods:We investigated these two RET pathways in a prospective series of 32 ACRO and 63 non-functioning
pituitary adenomas (NFPA), studying quantitative RNA and protein gene expression formolecular-clinical corre-
lations and how the RET pathway might be implicated in therapeutic success. Clinical data was collected during
post-surgical follow-up. We also established new'humanized’ pituitary cultures, allowing 20 repeated passages
and maintaining the pituitary secretory phenotype, and tested ﬁve multikinase inhibitors (TKI: Vandetanib,
Lenvatinib, Sunitinib, Cabozantinib and Sorafenib) potentially able to act on the GDNF-induced RET dimeriza-
tion/survival pathway. Antibody arrays investigated intracellular molecular pathways.
Findings: In ACRO, there was speciﬁc enrichment of all genes in both RET pathways, especially GDNF. ARF and
GFRA4 gene expressionwere found to be opposing predictors of response to ﬁrst-line therapy. ARF cut-off levels,
calculated categorizing by GNAS mutation, were predictive of good response (above) or resistance (below) to
therapy months later. Sorafenib, through AMPK, blocked the GDNF/AKT survival action without altering the
RET apoptotic pathway.
Interpretation: Tumor ARFmRNAexpressionmeasured at the time of the surgery is a prognosis factor in acromeg-
aly. The RET inhibitor, Sorafenib, is proposed as a potential treatment for resistant ACRO.
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We have been able to obtain a marker in the tumor of later resis-
tance to therapy, p14ARF. Ultimately, the ability to identify pa-
tients who are resistant to first-line therapy and the trial of new
pharmaceuticals should improve outcomes in acromegaly. Our
in vitro evidence discards some kinase inhibitors but proposes So-
rafenib as a putative treatment for those resistant patients. Using
this new culture system other therapies, even more selective for
RET, could be identified to later be tested in clinical trials.1. Introduction
Pituitary tumors are the 16% (11–22%) of intracranial neoplasms [1].
Acromegaly is a rare disease caused by a benign pituitary adenoma of
somatotroph cells (ACRO) secreting growth hormone (GH) (Orphanet:
963; GARD-5725). The majority of cases are sporadic, although familial
cases have been described [2]. Acromegaly has symptoms derived from
expansion of the tumor compressing the pituitary or the surrounding
structures such as the cavernous sinus, optic chiasma or hypothalamus.
Additionally, excess GH and consequently elevated IGF1 levels, produce
peripheral signs with growth of soft tissues and multiple comorbidities
(metabolic, cardiovascular, oncological, etc.; (reviewed elsewhere
[3–5]). First-line therapy initially comprises endoscopic surgery aiming
to cure the disease without damaging the remaining pituitary gland.
However, the surgical cure rate is only around 50% (40–69%), being in-
versely related to tumor size and invasiveness outside the sella turcica
[6]. Patients not cured by surgery undergo adjuvant therapy with ﬁrst-
generation analogs of somatostatin (fgSSA), the main hypothalamic
neuropeptide that inhibits GH secretion [7]. However, only half of pa-
tients not cured by surgery respond to fgSSA [8]. In fgSSA-resistant
cases second-line therapies include combined treatment with dopa-
mine analogs, pegvisomant or pasireotide, and even re-intervention or
radiotherapy. These procedures have a range of side effects without
necessarily controlling the apparently benign tumor.
RET is a tyrosine kinase receptor activated by a ligand in the pres-
ence of a membrane co-receptor [9]. In mammals there are four differ-
ent ligands for RET (Glial cell line-Derived Neurotrophic Factor
(GDNF), Neurturin (NRTN), Artemin (ARTM), Persephin (PSPN)) and
four respective co-receptors (GFRA1–4) [10,11]. In addition to the
respective ligand-co-receptor interaction, some cross-interactions
between ligands and co-receptors able to activate RET have been de-
scribed. Normal human and rodent somatotrophs express RET, GDNF
and GFRA1 [12,13], with RET working as a dependent receptor, a mech-
anism shared by a few other receptors [14]. Thus, in the absence of
GDNF its ligand RET is processed at themembrane by Caspase-3 and in-
duces overexpression of PIT1, leading to induction of the CDKN2A/ARF
promoter and ARF mRNA expression; p14ARF protein then binds to
and inhibits MDM2, leading to p53 accumulation and apoptotic cell
death [15,16].When GDNF is present, RET dimerizes, activating its tyro-
sine kinase which induces AKT and cell survival. Thus, somatotrophs
rely on the presence of the RET ligand GDNF for survival.
Immunohistochemical studies have shown that ACRO are the only
pituitary adenomas expressing all three proteins, RET, GDNF and
GFRA1 [13]. More recently, in vitro experiments in nine acutely dis-
persed ACRO have suggested that ACRO maintain the RET/PIT1/ARF/
p53 apoptotic pathway and need GDNF expression to survive [17]. In a
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to PIT1 expression [17]. To date, no studies have shown whether other
ligands or GFRA receptors are expressed in ACRO, nor are there any
data relating to the clinical relevance of the RET/PIT1/ARF/p53 apoptotic
or the RET/GDNF survival pathways in acromegaly.
In this prospective study our goal was to investigate the role of each
of these RET pathways in acromegaly, speciﬁcally in relation to clinical
tumor characteristics, response to treatment and prognosis. Addition-
ally, we carried out in vitro tests on ﬁve multikinase inhibitors able to
act on the GDNF-induced RET dimerization/survival pathway. Our
main ﬁndingwas that Sorafenib, a RET inhibitor, is a potential therapeu-
tic agent in resistant ACRO.
2. Materials and methods
2.1. Study design and clinical data
This study followed the European Convention on Human Rights and
Biomedicine (ETS n°164) reﬂected in the Spanish Law of Research in
Biomedicine (14/2007). This was a prospective study of acromegaly
(ACRO) patients recruited from October 2010 till February 2017 from
three hospitals in Spain: Hospital Clinico Universitario de Santiago de
Compostela (CHUS, N = 20), Hospital Universitario La Paz de Madrid
(N = 6) and Hospital Universitario de León (N = 4). Two patients
underwent reoperation. The study was approved by both a national
ethics committee based in Hospital Virgen del Rocio (Sevilla) (Act 1/
2010), as part of a national registry of Acromegaly (REMAH node
6) [18], and an institutional committee at CHUS, where the molecular
analyses were performed. Approved written consent was obtained
from each patient participating in the study. Patients underwent endo-
scopic endonasal transphenoidal surgery. Non-functioning pituitary ad-
enomas (NFPA)were also prospectively collected in CHUS (N=50) and
Leon (N= 13) for comparison with ACRO at the molecular level.
The study was designed following REMARK guidelines [19] (http://
www.equator-network.org/reporting-guidelines/reporting-
recommendations-for-tumour-marker-prognostic-studies-remark/)
(adapted to endocrine tumors). N ≥ 5 was calculated as the sample size
in a group to obtain signiﬁcant differences. Sample size calculations
were based on the known failure of ﬁrst-line therapy [6–8]: surgery fail-
ure has been reported to vary from 31% to 60% in previous series; of re-
maining non-surgically cured patients, half will not respond to therapy
with fgSSA, meaning that 15.5% to 30% of patients can be expected to be
Resistant. So to have N ≥ 5 in the Resistant group the current study
needed to have a total size of 17–32 patients, andwe therefore included
32.
Clinical data from ACRO were collected at the end of follow-up by
one Clinical Endocrinologist in a pre-designed Excel ﬁle. Variables in-
cludedwere based on current guidelines [6,7,20] and are shown in Sup-
plementary Table 1: gender; age; GH at diagnosis and after surgery;
IGF1 index (deﬁned as serum levels respective to the upper level of nor-
mality for the corresponding life decade) at diagnosis and after surgery
(the most relevant within 4–24 weeks); maximal diameter of the ade-
noma in the magnetic resonance imaging (MRI), volume calculated
from three diameters of the tumor, Knosp (grades of invasion of
cavernous sinus), invasiveness (at MRI, extension of the tumor in any
structure outside the sella turcica); cured at surgery (when IGF1 index
4–24 weeks after surgery was normal ≤1; if IGF1 index was repeatedly
found to be 1–1·5, an Oral Glucose Tolerance Test was performed to as-
sess curing); adjuvant therapy with SSA analogs (fgSSA, treatment with
ﬁrst-generation analogs, Octeotride-LAR or Lanreotide autogel); resid-
ual tumor (presence of tumor rest at control MRI 4–24 weeks after sur-
gery); response to SSA analogs (Complete: normalization of IGF1 index
after 6 months of treatment; Partial: when not normalized but there
was a reduction of 50%); response to ﬁrst-line therapy (The patient
was either cured by surgery or responded to adjuvant SSA analogs);
other treatments for those who did not respond to ﬁrst-line treatment(pegvisomant, radiotherapy).Molecular data were analysed in pituitary
tumor surgical surpluses by a single laboratory in Santiago de
Compostela (CIMUS).
2.2. Tissue sample management
Adenoma tissue surplus was immersed directly in RNA Later
(AM7021, Ambion, Netherlands), kept at 4 °C for 24 h, during which it
was couriered to Santiago de Compostela, where it was kept at −20
°C for another 24 h and stored at−80 °C until further use. From 2014,
for surplus tissue samples N10 mg at CIMUS, a small fresh piece was
transferred to the culture room for h7H primary culture (see below).
2.3. RNA and DNA extraction
Nucleic acids were extracted using an AllPrep DNA/RNA Mini Kit
(80284, Qiagen, Germany), in which DNA is ﬁrst puriﬁed in an afﬁnity
column, and RNA is then puriﬁed from the eluted fraction in a second af-
ﬁnity column which includes treatment with an RNasa-Free DNase Set
(79254, Qiagen, Germany). DNA was QC and quantiﬁed using a
Quantiﬁler Human DNA kit (4343895, Applied Biosystems, UK). RNA
was QC and quantiﬁed using a Nanodrop 2000 spectrophotometer
(Thermo).
2.4. qRT-PCR assay
500 ng of total RNA were incubated with 0.5 IU RNAse free DNAse I
(EN0521, Thermo), 1 microL 10× buffer and water as a total volume of
10 microL, at 37 °C for 30 min. The reaction was termnated by adding
1 microL 50 mM EDTA and heating at 65 °C for 10 min. cDNA was ob-
tained after adding 1.5 microL with 300 IU MMLV (28025–013,
Invitrogen, USA) and 6 microL 5× First-Strand Buffer and, following
the supplier's protocol, 1·5 microL 10 mM dNTPs, 0·1 microL Random
Primers, 3 microL 0·1 M DTT, 1microL RNaseOUT™ Recombinant Ribo-
nuclease Inhibitor (40 units/microL) and H2O in a 30 microL reaction.
50 ng, 25 ng and 12·5 ng of a commercial human Pituitary Gland Poly
A+ mRNA pool (1305204A, Clontech, USA) was similarly reverse-
transcribed in three independent reactions to use as a technical control.
Expression was detected by qPCR using 1 microL of the cDNA reaction
plus 6 microL 2× TaqMan Gene Expression MasterMix (4369016 Ap-
plied Biosystems) and 6 microL diluted primers in 96 well plates in a
7500 Real-Time PCR System (4351105, Applied Biosystems, USA). For
primers, when possible we used commercial Taqman Gene expression
primer sets (Applied Biosystems) (see Supplementary Table 5). When
isoforms or highly homologous genes were involved, (FSHB, LHB,
SSTR2 and SSTR5), we used previously validated primers (See Supple-
mentary Table 5) [1] with 6 microL Brilliant III Ultra-Fast SYBR
MasterMix (600,882, Agilent Technologies, USA). GH isoformmRNA ex-
pression was detected by both assays. Each 96 well plate was used for a
single gene reaction including duplicate samples of a group of 10 ACRO,
20 NFPA together with technical positive controls, negative control
(ACRO9 reverse-transcribed in the absence of MMLV) and blank (all re-
agents without cDNA).
As control for general gene expression we used TBP based in pub-
lished works [21,22] (http://www3.appliedbiosystems.com/cms/
groups/mcb_marketing/documents/generaldocuments/cms_042279.
pdf) and our previous experience [7]. ACTB is not considered a good
control because it shows higher variability between samples from the
same and from different tissues. TBP is considered as a gold standard
control for quantitative mRNA assays as it shows a more stable expres-
sion pattern in different human tissues and cell types. The ΔCt method
was used to express the results for each gene (ΔCtgene = Ctgene
− CtTBP). We calculated some of the data using both TBP and ACTB
and obtained similar results and statistical signiﬁcance.
Genes that were undetectable in a sample (Ctgene N 40) were classi-
ﬁed according to the CtTBP. If other samples with a similar CtTBP had a
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have a very low expression for that gene and its Ctgene transformed to 42
(two cycles over the limit). If a sample had a CtTBP that was higher than
any other sample, it was considered to be technically undetectable for
that gene (a lost sample for statistical comparisons). The mean of the
three concentrations of the technical control (commercial human pitu-
itary gland pool) was considered as 1. The ΔΔCt method, ΔCtgene-sample
−ΔCtgene-technical control, was used to calculate the end value of the
qPCR in each sample. Potency of 2−ΔΔCt was the end result used for sta-
tistical comparisons.
2.5. GNAS mutational proﬁle and STR analysis
The GNAS gene was ampliﬁed from 50 ng DNA by PCR (primers in
Supplementary Table 5) using 0·5 IU DreamTaq DNA Polymerase
(EP0701 Thermo Scientiﬁc), 2·5 microL DreamTaq Buffer, 0·5 microL
10 mM dNTPs, 0·5 microL 5microM Forward Primer and 0·5 microL 5
microM Reverse Primer and dH20 to a ﬁnal volume of 25 microL. The
PCR Product was Sanger-sequenced to check for mutations in nucleo-
tide C601/codon R201 or nucleotide A680/codon Q227 (Supplementary
Fig. 1a, Supplementary Table 3).
For assessment of similarity betweenpituitary tissue andprimary cul-
ture DNAwe used a combined panel of 16 STR AmpFiSTR NGM Select kit
(4457889, Applied Biosystems, Germany) including Identiﬁler Plus Panel
V1 (Applied Biosystems) as the read-out pattern. The 16 STR proﬁles ob-
tained were compared to the 8 STR American Type Culture Collection
(ATCC) database, using the ATCC Match algorithm according to ICLAC
standards (https://www.lgcstandards-atcc.org/en/STR_Database.aspx).
2.6. Long-term primary culture of human pituitary adenomas under hu-
manized (h7H) conditions
Previously [23,24], we designed a cell culture medium for human
follicular thyroid cells, h7H, in which all components and additives
were at concentrations within the human physiological ranges (based
on reference values for human serum from the Mayo Clinic wherever
possible (http://www.mayomedicallaboratories.com/test-catalog/)). In
current study, based in our experience in short-term rodent and
human primary pituitary cultures [16,17,25,26], the h7H medium was
slightly modiﬁed from the follicular thyroid medium: while insulin, so-
matostatin and cortisol were maintained; bTSH and hGH were re-
moved, and GHRH, Ghrelin, EGF, bFGF, T3 and Glucagon were added.
(Supplementary Table 6: h7H components are listed in seven groups
as osmolality and ions, hormones, growth factors, oligo elements, anti-
oxidants and vitamins, metabolites and ethanol. The medium also in-
cluded 10% serum (5% FBS and 5% NBCS)).
The excised fragment of the adenoma surplus was digested in
1 mg/mL collagenase IV (C9891-AG, Sigma, Israel) and 1× trypsin
(T4674, Sigma, USA) in PBS for 45 min, and then ﬁltered into complete
h7H medium (including serum, Supplementary Table 6) through a 41-
micron ﬁlter (NY4100010, Merck Millipore, Ireland) to remove undi-
gested tissue fragments. Cellswerewashed several timeswith complete
h7Hmedium and then seeded in one well of a 12-well TC-treated poly-
styrene plate (Costar, Thermo Scientiﬁc, USA). Every two weeks, cells
were trypsinized and diluted 1:2. We performed h7H culture in 11
NFPA y 4ACRO, ofwhich8NFPA and 3ACRO grewandweremaintained
for at least 21–33 passages. At the last passage, cells stop growing and
were able to remain passively attached to the plate for weeks (looking
senescent). Passages attained by cultures presented in current work
were: ACRO28 reached p21; ACRO30 reached p23; ACRO32 reached
p24; NFPA41 reached p33.
2.7. Analysis of secreted hGH and GDNF
For hGH secretion culture medium from plates was collected before
passaging, after three-four days with the cells, and stored at −80 °C.Immediately after, cells were trypsinized and counted for the next pas-
sage, so the precise number of cells in the dish, and the precise time of
incubation was known.
Clinical kits to determinehGH in human serum can have negative in-
terferences in samples of culturemediumcontainingbovine serumwith
heterophylic antibodies and higher biotin concentrations. This hap-
pened to us when we used the Immulite 2000 (Siemens Healthineers,
Erlanger, Germany) an IRMA type assay using a rabbit anti-hGH anti-
body conjugated to bovine calf alkaline phosphatase and beads coated
with murine monoclonal anti-hGH antibody; signal is detected through
chemiluminiscence. This kit have been previously used tomeasure hGH
regulation in acute cultures of primary ACRO adenomas [27]. In our
hands, measurements using 25 microL of whole medium (incuding
10% bovine sera) and this kit gave undetectable secretion in the
Immulite Siemens analyzer.
We decided to detect secreted hGHby loading 15microL of collected
medium onto a western blot in comparison with medium that was not
put into the cells. After a positive result in quantity, speciﬁcity and
molecular weight (Fig. 3), a second clinically validated assay was per-
formed in the culture samples after revision of the literature. The
COBAS hGH assay (Roche Diagnostics, Mannheim, Germany) had also
been previously used tomeasure hGH in culturemedium from pituitary
adenomas [28]. COBAS is also an IRMA type assay but without compo-
nents of bovine origin. 40 microL of sample medium is incubated with
a biotin labelled monoclonal murine anti-hGH antibody and a rabbit
polyclonal anti-hGH antibody conjugated to ruthenium chelate;
streptavidin-magnetic beads on a magnetic electrode purify the sand-
wiches, followed by an electromagnetic impulse to initiate the light
emission by the ruthenium that is detected in the Elecsys E170 auto-
matic analyzer.
For GDNF secretion, 10,000/well h7H-primary pituitary acromegaly
(or NFPA) cells were seeded in a 96-well dish, collected for different
time-lengths and kept at−80 °C. Secreted GDNF levels were measured
with a Human GDNF DuoSet ELISA (DY212, R&D Systems, USA) accord-
ing to the manufacturer's protocol. Brieﬂy, a 98-well microplate was
coatedwith the capture antibody and incubated overnight at room tem-
perature. Wells were blocked for 1 h at room temperature and stan-
dards and culture medium samples added and incubated for 2 h at
room temperature. Detection antibody was added during for 2 h at
room temperature. Avoiding exposure to light, streptavidin-HRP was
added for 2 min, followed by the substrate solution for a further
20min. After termination of the enzyme reactionwith the stop solution,
the plate was read at A450/A550nm in a microplate reader (Mithras LB
940, Berthold, Germany).
2.8. Immunocytochemistry
Procedures were performed as described [24]. Brieﬂy, h7H-primary
pituitary acromegaly cells were seeded and grown on glass coverslips
in a 48-well dish.Wells werewashed and ﬁxedwith 10% neutral forma-
lin for 30min,washed once and then incubated at room temperature for
20 min in methanol added at −20 °C. After further washing, perme-
abilization was carried out using Triton 0.2% in H2O on ice for one
hour. Primary and Secondary Antibodies are listed in Supplementary
Table 8.
2.9. Rat pituitary cell line GH4C1
The rat GH4C1 somatothroph cell line was cultured in DMEM
(D6046, Sigma, UK) containing 10% FBS [17]. Since no STR proﬁle has
been standardized for such rat cell lines, expression proﬁling was used
to assess phenotype (see Supplementary Fig. 3 and previous ref. [29]
to see constancy of phenotype). Transfection of RETL or RETS (Supple-
mentary Table 7) was performed using Nucleofector II (AAD-1001S,
Amaxa, Germany) with the A-20 program and L-kit (VCA-1005, Lonza,
Germany) as described [16].
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activity
TKIs (TINIB tools, Czeck Rep) stocks were prepared in DMSO and
kept at−20 °C. An essential step in our assay was deciding which TKI
concentrations tested in vitro were relevant for their in vivo action.
TKI concentrations were based on the United States Food and Drug Ad-
ministration (FDA) approved pharmacological review of each drug from
data collected in Phase II-III clinical trials.We selected themean concen-
tration at steady-state (CmSS) detected in treated patients' serum
(Supplementary Table 4).
h7H-primary pituitary acromegaly cells were seeded (10,000/well
in mw48 for apoptosis; 50,000/mw12 for RNA or protein extracts) in
full h7H medium with 10% serum. Two days later, cells were washed
and the medium changed to a deprived medium (0·5% FBS without
hormones or additives). Human GDNF (100 or 500 ng/mL, stock: 10
microg/mL in PBS containing 0·1%BSA; 345,872, Calbiochem, Israel),
NRTN (100 ng/mL; stock: 10 microg/mL in PBS containing 0.1%BSA;
1297-NE-025, R&D Systems, USA) or vehicle (PBS containing 0·1%
BSA)was added for 24h. A full h7Hmedium(with serumand additives)
condition was included as a control of basal apoptosis. Appropriate TKI
dilutions or DMSOwere added for the corresponding timewith/without
GDNF/NRTN.
For GH4C1 pituitary cells, 25,000 transfected cells/well were seeded
in a 48-well dish in full medium. The following day, cells were washed
and cultured in DMEM+0·1% BSA for 48 h with/without rat GDNF
(50 ng/mL PF039-10ugmicrog, Calbiochem, USA) and TKIs.
2.11. Apoptosis assay
Medium containing GDNF, TKIs or vehicles was added for 24 h
followed by addition of 5 microM Hoescht-33,258 (B1155, Sigma,
USA) for 1 h. Apoptosis was measured by live microscopy in an IX51
equippedwith CellSens software (Olympus). At least six ﬁelds including
75–100 cellswere registered perwell detecting condensedbrilliant blue
(apoptotic cells) and homogeneous soft blue (live cells).
2.12. 16-pad slide array
h7H-primary pituitary acromegaly cells were seeded and treated as
described above for one hour. Cells were washed with ice-cold PBS and
lysed with 30 microL of ice-cold Cell Lysis buffer (#7018, Cell Signaling
Technology, USA). MicroBCA Protein Assay (23,235 Thermo IL USA)was
used tomeasure protein concentration. The 16-pad PathScan Intracellu-
lar Signaling array kit (#7323, Cell Signaling Technology, USA)was used
according to the manufacturer's instructions. In brief, the array was
blocked using the array blocking buffer for 15min at room temperature.
60 microg cell lysates/100 microL Array Diluent Buffer was then added
and incubated for 2 h at room temperature on an orbital shaker. After
washing, Detection Antibody cocktail was added and incubated for 1 h
at room temperature. After washing, HRP-linked streptavidin was
added and incubated for 30 min at room temperature. After washing,
the Array glass slide was ﬁnally covered with 1× LumiGLO©/Peroxide
solution and exposed to ﬁlms in a linear time-course. The average
pixel density of each marker was scanned and quantiﬁed by Quantity
One (Bio-Rad) and normalized to pixel densities of the positive control
spots.
2.13. Cell extracts and Western blot
A small fragment of frozen acromegaly tissue was mixed with 100
microL lysis buffer (0.05 M Tris-HCl, 0.01 M EGTA, 1 mM EDTA,
16mMTriton X-100, 1mMsodiumorthovanadate, 0.05M sodium ﬂuo-
ride, 0.01M sodium pyrophosphate and 0.25M sucrose, adjusted to 7·5
pH (all reagents from Sigma, USA), with freshly added Complete EDTA-
free protease inhibitor cocktail tablets (11,836,170,001 RocheDiagnostics, USA). A Pit-Mill tissue lyser (85,300 Qiagen, Germany)
was used for three minutes at 20 Hz. Lysates were centrifuged at
12000 rpm for 30 min and supernatants stored at−80 °C.
Cell lysates obtained for the above 16-path slide array were consid-
ered cytoplasmic. For extractions that included membrane proteins,
wells were incubated for 20min on icewith 30microL of ice-cold Triton
lysis buffer (50mMHepes pH 7·5, 1% Triton X-100, 150mMNaCl, 5mM
EGTA, 1·5 mMMgCL, 10 mM Na pyrofosfate, 92 microg/mL Na3VO4, 2
microg/mL aprotinin and 4 mM PMSF, all reagents from Sigma, USA).
For total cell extracts 15 microL of boiling 1% SDS/well were added to
each well, which was then scraped and boiled at 95 °C for 5 min in a
thermoblock, and ﬁnally diluted 1:3 in Triton lysis buffer [17].All lysates
were centrifuged at 12000 rpm for 10 min and supernatants stored at
−80 °C.
MicroBCA Protein Assay (23,235 Thermo IL USA) was used to mea-
sure protein concentration. 15–20 microg of protein extracts run in
10–15% SDS-PAGE were electrotransferred to a PVDF membrane
(Immun-Blot PVDF 162–0177; Bio-Rad, USA) with a semidry blotter.
Membranes were blocked with 0·2% Tropix i-block (T2015, Applied
Biosystems, USA) in 1× TBS for 2 h. Antibodies and dilutions are
shown in Supplementary Table 8. Enhanced chemiluminescence assay
(Pierce ECL Western Blotting Substrate, 32,106, Thermo Scientiﬁc,
USA) was used for signal detection. Membranes were exposed to X-
ray ﬁlm (4741 19,289, Fujiﬁlm, Japan) and developed (Developer
G150, AGFA HealthCare, Belgium) and ﬁxed (Manual Fixing G354,
AGFA HealthCare, Belgium). Statistical analysis Statistical analysis and
plotting of graphs were performed using GraphPad Prism 6 (GraphPad
Software, USA), SPSS Statistics 20 (IBM, USA) and Corel Draw Graphic
Suite 2017. Analysis were performed in an independent way by CVA’s
group and the Mathematics Medical Department at CHUS. Graphs
show mean±SEM. Normality for each group of quantitative data was
assessed using the Kolmogorov-Sminorv test with Dallal-Wilkinson-
Lillie for ‘p’ value. The majority of the groups were non-parametric.
For statistical comparisons we performed detailed bi-variant analysis.
As the initial step in analysis of the data, correlations were assessed
with Spearman’s Rho (rs) and signiﬁcance. Quantitative variables
were compared by Mann-Whitney tests when non-parametric or un-
paired t-tests when parametric. Qualitative variables were compared
with a Chi-square independence test, using the Pearson ‘p’ value when
nN5 or the Fisher exact ‘p’ value when nb5. ANOVA was used for com-
parisons of more than two groups; for culture experiments, where
there was one control with no treatment, Dunnet’s correction was ap-
plied. For the multivariate analysis (response to ﬁrst-line treatment
and ARF expression cut-off depending on GNAS mutation) we used
Chi-squared with multivariate contingency table analysis. To calculate
the discriminating threshold for ARF (and GFRA4) expression, a ROC
curve was used.
3. Results
We analysed quantitative RET pathway gene expression in a pro-
spective series of 32 sporadic ACRO surgical samples collected in
2010–2017, in relation to clinical characteristics, and expression of
knownACROgenes and theG-protein subunitα (GNAS)DNAmutation,
a recurrent mutation found in sporadic ACRO (Supplementary Table 1
and Supplementary Fig. 1a). In summary, 30 new patients and two un-
dergoing reoperations were recruited from three hospitals (Santiago de
Compostela, Madrid and León), comprising 66·6% females, median age
45·6 years old and median follow-up 4·2 years (Supplementary
Table 2). 25% of samples contained mutated GNAS (Supplementary
Table 2 and 3). The clinical characteristics of our series do not differ
from other published series [30]. The majority of patients had a
macroadenoma, with tumor volume and diameter being inversely re-
lated to age but positively related to GH and IGF1 levels, Knosp grade
and invasion (Supplementary Table 2). Half of the patients (N = 16)
have received pre-surgery therapy with fgSSA, although no correlation
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Presence of GNAS mutation was not related to any other variable. Suc-
cess of surgery was correlated with smaller, less invasive tumors that
secreted less GH/IGF1. Resistance to adjuvant therapy with fgSSA was
just signiﬁcantly greater in males than females (p = 0·049) but had
no other signiﬁcant correlation. An improved response to combined
ﬁrst-line treatment was observed in older patients (p = 0·049) and
smaller non-invasive tumors but had no other signiﬁcant correlation.
3.1. Molecular taxonomy of the RET pathway in ACRO
Quantitative RNA expression analysis, using TaqMan qRT-PCR, was
performed for the following gene groups: pituitary hormones (GH iso-
forms; PRL; POMC/ACTH; CG-alpha, the common alpha subunit for
FSH, LH and TSH; and the speciﬁc beta subunits of the two gonadotro-
pins, FSHB and LHB), our pathways of interest (RET receptor as total ex-
pression RETN, long RETL and short RETS isoforms; its four co-receptors
GFRA1-2-3-4 and its four ligands GDNF, NRTN, ARTM and PSPN; PIT1
transcription factor; p14ARF isoform from the CDKN2A gene (here
called ARF); and p53), hypothalamic neuropeptide receptors (GHRHR
and somatostatin receptors SSTR2, SSTR5), other pituitary transcription
factors (PROP1, SF1, TPIT), AIP as a gene implicated in familial pituitary
adenomas (FIPA) [2], and two cell cycle genes previously studied in
models of acromegaly (CDKN1A/p21 and CDKN1B/p27) (see Supple-
mentary Fig. 1 for a comprehensive scheme of the genes studied). We
compared all genes with a commercial pool of pituitary poly-A mRNA
as a technical control for each gene, to equalizemeasurement efﬁciency
from different plates during the study.
First, we identiﬁed a common proﬁle of genes enriched in ACRO, to
allow us subsequently to evaluate individual samples. To assess enrich-
ment, we compared the expression of each ACRO gene with a similar
prospective series of Non-Functioning Pituitary Adenomas (NFPA, n
= 63). As expected, GH (22KDa (GHTaq) and 20 KDa (GHSyb) iso-
forms), GHRHR, SSTR2 and SSTR5 were very abundant in ACRO in com-
parisonwithNFPA (Fig. 1a). Therewas nodifference between ACROand
NFPA in expression levels of other non-somatotroph hormones, such as
POMC (corticotroph hormone), CG-alpha or LHB (the beta subunit of
the LH, one of the two gonadotroph hormones) (Supplementary
Fig. 1b). However, FSHB (the beta subunit of FSH, the other gonadotroph
hormone) was signiﬁcantly enriched in NFPA (Supplementary Fig. 1b).
From the RET receptor downstream, all genes in the RET pathway
were signiﬁcantly more highly expressed in ACRO than in NFPA
(Fig. 1a). Especially abundant were the ligand GDNF, the somatotroph
transcription factor PIT1 and the tumor suppressor ARF, while a smaller
difference was found in p53, attributable to its regulation being at the
protein level. Of the three non-somatotroph transcription factors stud-
ied, PROP1 presented low expression in all tumors, although it was sig-
niﬁcantly higher in ACRO than in NFPA; as expected, SF1 was
signiﬁcantly higher in NFPA, while TPIT was poorly expressed in both
ACRO and NFPA, attributable to the fact that it is characteristic of
corticotroph tumors (ACTH series) (Fig. 1a). AIP, a protein related to fa-
milial but not sporadic acromegaly [1], did not show differences in ex-
pression between ACRO and NFPA (Fig. 1A). p21, a gene activated by
p53, was more abundant in ACRO (Fig. 1a), contrary to p27 that did
not present differences (Supplementary Fig. 1b).
After this initial characterization of the ACRO series, each sample
was individually evaluated for its level of enrichment of the most
abundant somatotroph genes (GH, GHRH, PIT1) and depletion of
non-somatotroph genes (TPIT, POMC, SF1, CG-alpha, FSHB, LHB) (Sup-
plementary Fig. 1c). PRL was considered a ‘neutral’ gene as it can be
co-secreted with GH. All samples passed our technical control, although
two samples, ACRO23 - a re-operation following radiotherapy - and
ACRO39, expressed some non-ACRO genes (Supplementary Fig. 1c).
However, the level of GH expression in these two samples was still
much higher than that in NFPA and thus they were included. PRL was
co-expressed with GH in three samples: ACRO19, 25 and 32. Weproceeded with our study in the conﬁdence that the tissue from
which we had extracted RNA was mainly ACRO.
Fig. 1b shows the RET pathway in normal somatotroph cells [15,16].
In the absence of the ligandGDNF, RET is a dependence receptor: the in-
tracellular region is processed by Caspase-3, generating an intracellular
fragment IC-RET and activation of PKC delta (PKCd); this induces PIT1
overexpression, exceeding permissive levels of an already abundant
gene and inducing ARF expression. ARF binds to and blocks MDM2,
the protein that ubiquitinates p53 prior to its destruction, leading to
p53 accumulation and apoptosis. If the ligand is present, GDNF induces
RET dimerization which inhibits the apoptotic pathway, activating AKT
and maintaining regulated PIT1 expression, which is sufﬁcient to pro-
duce GH but not to induce apoptosis [15,16]. This pathway explains
the abundance of GDNF both in the normal pituitary (containing
50–60% of somatotroph cells) and to a greater extent in ACRO (Fig. 1a).
RET has a long (RETL) and a short (RETS) isoform varying in the
length of its cytoplasmatic C-terminal tail, leading to different number
of tyrosines candidates for phosphorylation and hence interaction
with different substrates (Fig. 1b, right). As stated above, each RET co-
receptor binds a characteristic ligand (GDNF-GFRA1, NRTN-GFRA2,
ARTM-GFRA3, PSPN-GFRA4). (see STRING, https://string-db.org/cgi/
network.pl?taskId=Unm9pNIMfJex). It is well established that GDNF
activates RET through GFRA1 [31,32]. It has also been demonstrated
that NRTN is able to activate RET through GFRA2 more potently than
GDNF [33]. However, there is also cross-activation between ligands
and co-receptors, as shown by transfection experiments and in primary
culture. Thus NRTN is able to fully activate RET with equal potency to
GDNF through GFRA1 in transfection studies although it does so slightly
less potently than GDNF in primary cells expressing GFRA1 receptor
(Fig. 1b) [33–36]. ARTM and PSP are less potent than GDNF or NRTN
but still able to activate RET through GFRA1 in cells expressing the re-
ceptor [35–37].
In the ACRO series studied, expression of RETL and RETS isoforms
were similar as approximate halves of total RET expression (RETN)
(Fig. 1c). The co-receptor most abundantly expressed was GFRA1
followed byGFRA4 (Fig. 1c). This ﬁttedwith themajor ligand expressed
being GDNF, followed by NRTN and PSPN (Fig. 1d).
We calculated correlations between molecular variables. Spearman
correlations were used to investigate gene expression and GNAS muta-
tion. Signiﬁcant but relevant correlations (Rho, rs N 0·36) are shown in
Fig. 1e. Expression of GDNF was positively correlated with NRTN and
ARTM ligands, and both RET isoforms. Both GDNF and NRTNwere neg-
atively correlated with PIT1 but positively correlated with PROP1. PIT1
and PROP1 were negatively correlated with each other. PROP1 directly
induces PIT1 expression during embryonic development, and once
PIT1 is induced PROP1 is repressed through a mechanism that is
known not to be directly repressed by PIT1 [38,39]. GFRA1 and SF1
were also positively correlated with PROP1. ARF expression was posi-
tively correlated with GH, GHRHR, AIP, ARTN and TPIT. SSTR2 was
only correlated with GH expression. No correlations were found for
p53, which was not unexpected as p53 is regulated mainly at the pro-
tein level. All other genes studied (including p21 and p27) and GNAS
mutations were found not to be relevantly correlated.
Molecular correlations were somewhat reduced in signiﬁcance
when the group of naïve samples (N = 16) was analysed separately
from the group with pre-surgery treatment (N = 16) (Supplementary
Fig. 1d). This was expected as a consequence of halving the samples.
However, the weakest correlations were lost including PIT1-GDNF,
PIT1-PROP1, PROP1-NRTN, ARF-AIP and GH-SSTR2 (Fig. 1e, yellow or
blue dots). When genes implicated in these lost correlations were
analysed for differences between both groups we found signiﬁcant dif-
ferences exclusively in PIT1 and GH expression that is reduced, particu-
larly GH, in pre-surgery treated samples (Fig. 1f).
The most relevant ﬁnding from these data was that the GDNF-RET
survival pathway is strongly expressed in acromegaly and reinforced
by redundancy in expression of RET ligands and RET receptor isoforms,
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prompted us to further explore the RET pathway in relation to clinical
follow-up characteristics of the patients.
3.2. ARF is a prognostic factor of response to ﬁrst-line combined treatment
(surgery+fgSSA) in acromegaly
We investigated correlations between molecular and clinical vari-
ables, which were divided into three groups: diagnostic, pathologic
and prognostic/follow-up. In Fig. 2A signiﬁcant and relevant (rs ≥ 0·5)
correlations are shown.
Of the analytical diagnostic variables, only basal serumGHat diagno-
sis was signiﬁcantly correlated with GH, SSTR2, AIP and p53 RNA tumor
expression, all of which were abundantly expressed in ACRO (Fig. 2a
left). Pre-surgery therapy was negatively correlated with PIT1 and GH
(Fig. 2a). This was expected since expression of those two genes were
reduced with the treatment (Fig. 1e).
Regarding pathologic variables, two genes showed important corre-
lations, ARF and TPIT. ARF expressionwas negatively correlatedwith in-
vasiveness, Knosp grade and, importantly, with post-surgical residual
tumor (Fig. 2a center). TPIT expression was negatively correlated with
tumor diameter/volume, invasiveness and Knosp grade, but positively
correlated with surgical cure (Fig. 2a right).
In the group of prognostic variables, response to fgSSA during
follow-up was strongly and positively correlated with ARF expression
(rs N 0·8), while GFRA4 was negatively correlated (rs N 0·7). Other
genes less strongly correlated ith response to fgSSA were GH, TPIT and
SSTR2 (rs 0·5–0·6). Since expression of the genewith the twomost im-
portant correlations, ARF, was also related to a favorable course of dis-
ease (negatively correlated with residual tumor and positively
correlated with response to fgSSA), we combined the two prognostic
variables into a single ‘Good Prognosis’ Group 1, deﬁned as responsive
to combined ﬁrst-line therapy (surgery + fgSSA). When this group
was analysed for correlations, ARF expression showed the highest pos-
itivity (rs N 0·7) and signiﬁcance, followed by TPIT (rs = 0·6), while
GFRA4 was negatively correlated (rs = 0·5).
Molecular-clinical correlations were maintained, although with re-
duced p values, when analyzing separately naïve and pre-surgery ther-
apy groups (N = 16 each) (Supplementary Fig. 2a), with some
exceptions (Fig. 2a: yellow dots, lost in pre-surgery therapy; blue dots
lost in naïve). Correlation between SSTR2 and basal GH at diagnosis,
and TPIT and volume did not exist in naïve samples. Correlations be-
tween ARF and invasiveness, and SSTR2 and Response to fgSSA were
lost in the group with pre-surgery therapy. All other correlations, espe-
cially those implicating ARF and GFRA4 with response to 1st line ther-
apy were strongly maintained in both groups (Compare Fig. 2a and
Supplementary Fig. 2a).
We then compared Group 1 with ‘Resistant’ Group 0, deﬁned as not
cured by surgery and resistant to fgSSAduring follow-up. ARFmRNAex-
pression values were much lower in Group 0 than Group 1 (MannFig. 1.mRNAexpression characterizing ACROand the RET pathway. a)Quantitative RNA express
every sample, gene expressionwas normalized to a commercial pool of pituitary poly-AmRNA (
functional pituitary somatotrophs, related to GH secretion (GHTaq (22 KDa), GHSybr (22, 20 and
receptor (RETN), its ligand GDNF and genes in the RET pathway regulated at the RNA level
upregulated in ACRO. SF-1 was characteristic of NFPA, and T-PIT of ACTH-secreting adeno
receptor, differing at the C-terminal tail (long RETL and short RETS), its four ligands and its
receptor, cross-interaction exists. In somatotrophs in the absence of ligand, RET is processe
pathway through overexpression of PIT1 gene inducing p14ARF expression, p53 accumulatio
tyrosine kinase activity leading to AKT phosphorylation and survival. c) In ACRO, both RET
receptors were expressed, the most highly expressed was GFRA1 (high afﬁnity for GDNF), fo
NTRN and PSPN also abundantly expressed. (ANOVA). e) Signiﬁcant correlations among all th
positively correlated with expression of RET isoforms and the other ligands. GDNF (and NRTN
As expected, expression of both transcription factors PIT1 and PROP1 were negatively corre
correlated with the somatotroph phenotype (GH, GHRHR, AIP), T-PIT and the ligand ARTN. (
was analysed separately from the group receiving pre-surgery therapy (N = 16). Yellow do
group. f) Genes implicated in lost correlations were not differentially expressed between b
therapy group (all Mann-Whitney test except ARF t-Test). (p b 0·05; **, p b 0·01; ***, p b 0·00Whitney test, p b 0·0001, Fig. 2c left). Similar results were obtained
when tumors not cured by surgery were analysed separately. ARF was
againmore highly expressed in samples responding to fgSSA than resis-
tant samples (Fig. 2c right). Differences between follow-up groups for
the other genes tested (SSTR2, SSTR5, TPIT, SF1) either did not reach
the ARF levels of signiﬁcance or were not signiﬁcant (Supplementary
Fig. 2c-d). Moreover, results did not change for ARF when ACTB was
used as the control gene, instead of TBP to normalize RNA expression
(Supplementary Fig. 2e). We then aimed to ﬁnd a cut-off value for
ARF expression which would classify an acromegaly as either Respon-
sive Group 1 or Resistant Group 0 at the time of surgery, by constructing
a ROC curve of ARF levels (Supplementary Fig. 2f). We found that plac-
ing the cutoff at ≥0·06 separated the groups with 100% sensitivity but
85·7% speciﬁcity. Placing the cutoff at ≥0·1, however, separated groups
with 96% of sensitivity and 100% speciﬁcity. Although these valueswere
very good as a clinical predictor we wanted to understand if there were
other factors that might explain the blurred separation of three samples
located at cut-off levels. In Group 1 the only value in the range 0·06–0·1
was in fact GNAS-mutated, while in Group 0 values in the same range
were non-GNAS-mutated. We did not ﬁnd any correlations between
GNASmutation and anymolecular or clinical variables studied (Supple-
mentary Table 2). Moreover, while themedian values were no different
between the GNAS-mutated and non-mutated groups, the range of ARF
expression in themutated groupwasmuch smaller (range 0·042–0·64,
n=8) than that in the non-mutated group (range 0·003–1·08, n=24)
(Supplementary Fig. 2 g). Therefore, a lower cut-off value would be ex-
pected for the mutated GNAS samples. In accordance with this, when
we separated Group 0 and Group 1 using a cutoff of 0·1 for ARF expres-
sion in non-mutated GNAS ACRO and 0·06 inmutated GNAS ACRO, and
performed amultivariant analysis using Chi-square test, we foundmax-
imal signiﬁcance (p b 0·0000) (Fig. 2d top), with all samples showing
100% sensitivity and speciﬁcity (Fig. 2d lower).
fgSSA include two prescriptions, Octeotride LAR (Octeotride, n= 5
patients) and Lanreotide Autogel (Lanreotide, n=13patients).We sep-
arated patients receiving each treatment and found that, again, ARF ex-
pression was able to separate Group1 from Group 0 for both treatments
(Supplementary Fig. 2 h). We performed statistics in the Lanreotide
group of patients, and again differences in ARF levelswere clearly signif-
icant between Group 0 (Resistant) and Group 1 (Responsive), in spite of
their reduced number.
GFRA4 was the only negatively correlated gene during follow-up
(Fig. 2b). When all samples were taken into account there were signiﬁ-
cant higher expression levels in Group 0 than Group 1, although the
gene was not a perfect classiﬁer (Fig. 2f left). Selecting samples that
were not cured with surgery and treatment with fgSSA (Resistant
Group 0, Responsive Group 1), GFRA4 expression was again signiﬁ-
cantly higher in Group 0, with a cutoff ≥0·1 (Fig. 2E right). There was
a single sample in Group 0 that did not follow this rule (yellow dot =
ACRO36), which was from a reoperation following radiotherapy in the
same patient as ACRO27. This could be because radiotherapy or fgSSAion comparingmean±SEMACRO (n=32, blue bars) andNFPA (n=56–63, pink bars). In
technical control;white bars). Genesmost highly expressed inACROwere characteristic of
17 KDa)), or PIT1 and hypothalamic regulation (GHRHR, SSTR2, SSTR5). However, the RET
(ARF and PIT1) were signiﬁcantly more abundant in ACRO than NFPA. p53 was slightly
mas (orange bar). (Mann-Whitney test). b) Cartoon representing isoforms of the RET
GFR-alpha co-receptors (GFRA1–4). Although there is preference of a ligand for a co-
d by Caspase-3 generating an intracellular fragment (IC-RET) that triggers a cell-death
n and apoptosis. When the ligand is present, RET dimerizes and activates its cytoplasmic
L and RETS are expressed in approximately equal amounts. Although all four RET co-
llowed by GFRA4. (ANOVA). d) GDNF was by far the most highly expressed ligand, with
e genes studied in ACRO (rs N 0·36) revealed that GDNF expression was signiﬁcantly and
) were negatively correlated with PIT1 expression but positively correlated with PROP1.
lated. PROP1 was also correlated with GFRA1 and SF1. ARF expression was signiﬁcantly
Spearman test). Weakest correlations were lost (p N .2) when the naïve group (N = 16)
ts: correlations lost in pre-surgery therapy group; Blue dots: correlations lost in naïve
oth groups except for PIT1 and GH that were signiﬁcantly reduced in the pre-surgery
1; ****, p b 0·0001; 0·0000 means lower p).
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for response to fgSSA limited to adenomas not cured by a ﬁrst operation.
To test whether the results obtained for gene expression were veri-
ﬁablewith protein expressionwe studied relevant protein expression in
a sub-set of samples (Fig. 2f). We compared one resistant sample
(ACRO27) with ﬁve responsive, either cured by surgery (ACRO7, 8) or
responsive to fgSSA therapy (ACRO9, 16 and 15). Only ACRO8 and
ACRO27 were naïve samples that had not been pre-surgically treated
with fgSSA, at least for a short time while waiting for the surgery (Sup-
plementary Table 1). As shown in Fig. 2g, ACRO27 contained high levels
of RET protein but negligible or low levels of PIT1, ARF and p53. OnlyACRO7, 8 and 27 had detectable GFRA4 expression, but the proteins de-
tected were of three different molecular weights. It has previously been
shown that GFRA4 has a canonical protein GPI isoform thatmakes a GPI
link on the extracellular aspect of the plasma membrane and functions
as a RET co-receptor, as well as a longer TM isoform with a transmem-
brane domain, and a shorter secreted isoform [40]. Thuswe could ascer-
tain that ACRO7 expressed the secreted GFRA4 isoform but ACRO8 the
TM isoform. Only ACRO27 presented the canonical GPI isoform able to
function as a RET co-receptor. Quantitative ARF protein expression, rel-
ative either to ACTB or GAPDH as loading controls, was well correlated
to ARF mRNA levels (Fig. 2g bottom).
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Acromegaly
Taken together, the data to this point indicated that the RET/PIT1/
ARF/p53 apoptosis pathway is maintained in ACRO that are responsive
to ﬁrst-line therapy, but blocked and re-oriented towards survival in
tumors that are resistant to ﬁrst-line therapy. To counteract apoptosis,
RET must bind GDNF, the main ligand in ACRO, dimerize and
activate survival pathways through its tyrosine kinase (TK) activity
[15–17,31–37]. Next, we therefore explored the possibility that any of
the TK inhibitors (TKI) currently used to treat neuroendocrine tumors
might be able to block the RET/GDNF survival pathway.
To do so we needed to develop a primary cell culture system that
would allow repeated experiments and dose-response analyses, while
maintaining characteristics relevant to the disease. Previously, we and
others have performed acute experiments with cell dispersions of
human ACRO or rat pituitaries in culture conditions that do not allow
cell growth or proliferation [15–17,25,26]. The few pituitary cell lines
with a somatotroph phenotype are rat, and not human, and do
not maintain the full secretory phenotype, expressing Gh and Pit1 but
lacking essential receptors like Ghrhr or very reduced Ret expression
(Supplementary Fig. 3). In 2012, we established new culture conditions
for human thyroid, h7H, inwhich all componentswere adapted to phys-
iological concentrations found in human serum [23]. Through culturing
normal and neoplastic follicular cells, h7H has led to the discovery of
speciﬁc mechanisms underlying human thyroid cancer [24]. We
adapted h7H medium for growing human pituitary adenomas by vary-
ing the hormone mixture (Supplementary Table 6). We successfully
(about 75% success) grew 8 NFPA and 3 ACRO (indicated as P-NFPA or
P-ACRO, Fig. 3a), which maintained their phenotype for at least
twenty-one passages (range 21–33, longer passages achieved for
P-NFPA). Cultures showed the same genetic identity proﬁles to the orig-
inal pituitary tissue, whichwas distinct from any knownhuman cell line
(Supplementary Fig. 4A). Cells grew slowly (with a passage 1:2 every
two weeks) and were positive for cytokeratins, GH, RET and GDNF
assayed immunocytochemically (Supplementary Fig. 4B). Human GH
was detected by western blot in the culture medium of the three P-
ACRO only after incubation, showing that it was being secreted during
culture (Fig. 3b, left). Quantiﬁcation of the hGH secretion with a kit
was speciﬁc for ACRO cultures while undetectable in NFPA or medium
with no incubation with the cells (Fig. 3b, centre). Normalizing the
amount secreted to the cell number on the dish valueswere normalized
for the three ACRO cultures to 1000–6000 pg/mL/104 cells/day (Fig. 3b,
right).
The phenotype was maintained through passages as shown for
mRNA expression of P-ACRO28 p3 to p15 (Fig. 2a), for hGH secretionFig. 2. ARF mRNA expression as a prognostic marker for ACRO resistant to ﬁrst-line combined
surgery. a-b: Signiﬁcant correlations (Spearman test, rs N 0·5) between mRNA expressio
Supplementary Table 1). Dots: blue, correlations not existing in naïve samples; yellow: co
correlated with GH, SSTR2 (only if pre-treated), AIP and p53. Centre: Pre-surgery therapy was
characteristics of the tumor (invasiveness (only if naïve), Knosp grade, residual tumor). Righ
(only if pre-treated), invasiveness and Knosp) but positively correlated with surgical cure. b
fgSSA (rs N 0·8). GFRA4 was the second-strongest marker but negatively correlated with re
with response to analogs (rs 0·5–0·6). Right: Combining ﬁrst-line treatments (surgery+fgSS
positively and negatively correlated markers, respectively, followed by TPIT (rs = 0·6) as a p
cured by surgery and resistant to analogs) and Group 1 (Responsive to ﬁrst-line treatment, ei
surgery was also performed. c) ARF expression was a good discriminator of Group 0 and Grou
0·0002). d) Samples were categorized with different cutoffs for non-mutated (GNASwt cutoff
e) A subanalysis of naïve patients and those with pre-surgery therapy including categorizin
group of patients with similar cutoffs. f) Left: Enhanced GFRA4 expression was not a good cla
Right: In the group of non-surgically cured, GFRA4 was a good classiﬁer in the opposite way
reoperations after radiotherapy (Group 0, yellow; Group 1, orange). g) Western blots of RE
GAPDH, ACTB) from ACRO tissue extracts (Group 1 (Responsive) and Group 0 (Resistant)). A
0) expressed high RET but low PIT-1 protein levels, correlating with absence of p14ARF and p
The RET co-receptor (GPI, canonical isoform) was highly expressed in ACRO27 (Group 0) w
Quantiﬁcation of ARF protein band intensity respect to controls, ACTB (yellow bars) or GA
Whitney test; d Chi-square test. *, p b 0·05; **, p b 0·01; ***, p b 0·001; ****, p b 0·0001; 0·00P-ACRO28 p6-p15, P-ACRO30 p6-p17 and P-ACRO32 p5-p6-p7-p12
(Fig. 2b). After passage 21, it arrived one passage where the cells stop
growing, increased size and reduced hGH secretion as seen for
ACRO32 p24 (Fig. 2b, centre).
Since GDNFwas themain RET ligand expressed in ACRO (Fig. 1a), we
also measured its secretion into the culture medium. Fig. 3c shows the
concentration of human GDNF (hGDNF) secreted by the three P-ACRO,
while no hGDNF was detected in either P-NFPA or medium cultured in
empty wells. In P-ACRO32 medium GDNF concentration increased as
the culture grew.
We selected ﬁve TKI, Vandetanib (V), Lenvatinib (L), Sunitinib (Su),
Cabozantinib (C) and Sorafenib (So), all FDA approved for treatment of
neuroendocrine cancers and known to inhibit RET kinase (Supplemen-
tary Table 4). A key step in our assaywas to decidewhich TKI concentra-
tions tested in vitro were relevant to their in vivo actions. We therefore
performed an in silico study to ascertain relevant mean concentrations
at the steady-state (Cmss), as detected in sera from patients treated
with the TKIs in Phase II/III clinical trials (Supplementary Table 4). Soraf-
enib was used at half this concentration since 10–20% of the patients re-
quired their dose to be halved due to serious side effects.
As shown in Fig. 3D, the three cultured P-ACRO maintained the RET
apoptotic pathway and presented marked apoptosis when deprived of
GDNF (by washing and replacing with low-serum medium) that was
inhibited by re-addition of GDNF (100 or 500 ng/mL). In the absence
of GDNF different TKIs affected RET-dependent apoptosis to different
extents. Only Sorafenib caused signiﬁcant and appropriate apoptosis
in the presence of GDNF, neutralizing the survival effect of both 100
and 500 ng/mL GDNF in the three cultures (Fig. 3D). We performed a
dose-response curve of Sorafenib in two of the cultures. In both P-
ACRO30 and P-ACRO32 2 and 4 microg/mL led to signiﬁcant inhibition
of the GDNF survival effect (Fig. 3E), suggesting that lower doses than
those required in cancer could be effective in acromegaly treatment.
Some ACRO showed a combined expression of GDNF and NRTN, the
second most important ligand for RET (Figs. 1B and 2F) which can
cross-activate RET through GFRA1 [33–36]. In accordance with this, in
our culture system NRTN alone or combined with GDNF was also a sur-
vival factor following ligand deprivation (Fig. 3F). We therefore tested
whether Sorafenib was able to counteract the survival effect of GDNF
or NRTNor the combination of both, and indeed found that it could neu-
tralize the survival action of each factor alone or in combination
(Fig. 3F).
ACRO tumors expressed both isoforms of the RET receptor, RETL and
RETS (Fig. 1C and 2F), which have distinct thyrosines and differentially
activating signal transduction pathways, either quantitatively (inten-
sity, duration) or qualitatively (activated signaling cascades) [10].
P-ACRO maintained expression of both RET isoforms in culturetreatment (sugery + fgSSA). GFRA4 as a prognostic marker only for those not cured by
n and clinical variables (diagnostic, pathologic and prognostic/follow-up) (See also
rrelations lost in the pre-surgery therapy group. a) Left: serum GH at diagnosis was
negatively correlated with GH and PIT1. ARF was negatively correlated with the negative
t: TPIT was negatively correlated with negative tumor characteristics (diameter, volume
) Left: ARF was the strongest positive marker for response to adjuvant treatment with
sponse (rs N 0·7). GH, TPIT and SSTR2 (only if naïve) showed some positive correlation
A) into a single category, ARF (rs N 0·7) and GFRA4 (rs = 0·5) were the most signiﬁcant
ositive marker. c-f: Patients were categorized into two groups, Group 0 (Resistant: Not
ther cured by surgery or controlled with analogs). A subanalysis of patients not cured by
p 1, both in the series as a whole (p b 0·0001) and in patients not cured by surgery (p=
0·1) or mutated (GNASmut, cutoff 0·06) GNAS; Chi-squared tests classiﬁed all samples.
g by GNAS demonstrated the ability of ARF to separate Group 0 from Group 1 in either
ssiﬁer for ACRO as some in Group 1 (Responsive, high ARF) had high GFRA4 expression.
to ARF, with high levels in Group 0 (Resistant to ﬁrst-line therapy). Coloured dots show
T pathway (RET, PIT1, ARF, p53) and ligand (GDNF, NRTN) proteins with controls (GH,
RF and GFRa4 protein levels corroborated mRNA levels described above. ACRO27 (Group
53. GFRA4 showed three different molecular weights corresponding to distinct isoforms.
hile ACRO7 and ACRO8 (Group 1) expressed different non-RET co-receptor isoforms.
PDH (orange bars), in relation to the ARF mRNA expression (blue bars). (c-e-f Mann-
00 means lower p).
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548 M. Chenlo et al. / EBioMedicine 43 (2019) 537–552(Fig. 3A). We investigated the anti-survival action of Sorafenib on each
RET isoform by using either RETS or RETL transfection into the rat pitu-
itary cell line GH4C1 that expresses GH, PIT1 and GDNF, but RET at very
low levels (Supplementary Fig. 3) [15,16]. In this set-up, Sorafenib was
able to block the survival action of rat GDNF (rGDNF) in the presence
of either human isoform RETL or RETS, much more effectively than
any of the other TKIs tested (Fig. 3G). The other TKIs (V, L, Su, C) were
able to counteract GDNF survival, but also affected the RET apoptotic
pathway in the absence of ligand (Fig. 3G).
We next investigated which signal transduction pathways activated
by RET/GDNF were being affected by Sorafenib. AKT has been impli-
cated in GDNF/RET survival in normal somatotrophs and acromegaly
[15,17]. We therefore performed an antibody array with extracts of
two primary acromegaly cultures, P-ACRO30 and P-ACRO32, treated
for one hour with/without GDNF plus/minus Sorafenib (Fig. 4A). Arrays
were scanned and quantiﬁed (Fig. 4B). Kinases signiﬁcantly activated by
GDNF were AKT and mTOR. Signiﬁcantly inhibited by GDNF were the
cleavage of Caspase-3 (cl-CASP3) and PARP (cl-PARP), two enzymes ac-
tivated by cleavage, as well as Ser15 phosphorylation of p53 (p-p53) a
sitewell-known for p53 stability and activity, all ofwhich are implicated
in apoptosis in somatotrophs [15,17]. Sorafenib blocked GDNF-induced
AKT/mTOR activation and increased cl-Caspase-3 and cl-PARP and
p-p53. Moreover, Sorafenib caused activation of p-AMPKa per se,
which was augmented in the presence of GDNF (Fig. 4B). To validate
the array results we performed western blots with extracts from
P-ACRO32, also treated with GDNF/Sorafenib for one hour. Lysates
were obtained with buffers optimised for enrichment in the plasma
membrane or cytoplasm. In parallel, whole cell extracts were treated
for 24 h, the time at which apoptosis or survival was clearly detectable
(see Fig. 3). As expected, GDNF induced RET phosphorylation at the
membrane (Fig. 4C). Sorafenib blocked this phosphorylation and even
reduced total RET expression. Previous studies have demonstrated
that in the absence of GDNF the RET apoptotic pathway is initially acti-
vated after a complex between RET and Caspase-3 is formed at the
membrane, resulting in both RET processing and Caspase-3 activation
by cleavage (IC-RET and cl-CASP3 fragments, respectively) [15]; this
also occurred in our experiment (Fig. 4C and D). When the cells are de-
prived of serum/GDNF cl-CASP3 increases but this was blocked in the
presence of GDNF as described [15,17]. GDNF in the presence of Sorafe-
nib recovered and even enhanced cl-Casp3 levels (Fig. 4C).
At the cytoplasmic level (Fig. 4D), GDNF induced phosphorylation of
AKT at (mainly) Thr450 and Ser473, whichwas blocked by Sorafenib. As
a corollary, GDNF-induced mTOR phosphorylation was also blocked by
Sorafenib, as was the mTOR-dependent phosphorylation of S6 kinase
(Fig. 4D). Deprivation induced RET processing with appearance of the
cytoplasmic Caspase-3 processed IC-RET fragment; RET processing is
inhibited by GDNF but recovered by Sorafenib (Fig. 4D). On the other
hand, Sorafenib alone induced AMPKa activating phosphorylation; this
activation was enhanced in the presence of GDNF. Similarly, Sorafenib
induced the activating phosphorylation of p53 that was enhanced –
and not inhibited- in the presence of GDNF (Fig. 4D).
After 24 h of treatment (Fig. 4E), PIT1 accumulated in serum-
deprived cells, leading to an increase in p14ARF. GDNF reduced bothFig. 3. Primary cultures of human acromegaly in humanized conditions (h7H) unveiled Sorafen
NFPA (P-NFPA41) cultured in h7H conditions grew for many passages while maintaining mRN
SSTR2 and 5; in NFPA, SF1. Data are normalized to the ﬁrst acromegaly P-ACRO28. Passage was
was secreted by cultured ACRO into the medium as demonstrated by western blot. Centre: Q
passaging. Right: Secretion was normalized by cell count and length of incubation with the cel
by NFPA, as demonstrated by ELISA. Secretion was increased as cells grew, as shown for ACRO
that was blocked by addition of GDNF (hatched white bars). Five TKIs used for other neuroe
Sorafenib (So)) were tested against the survival action of GDNF at clinically relevant concen
Some of the inhibitors enhanced RET-dependent apoptosis in the absence of GDNF (black
Sorafenib was the only TKI that potently blocked the GDNF survival effect in the three ACRO
toxic effect). e) Dose-response curve of Sorafenib in P-ACRO30 and P-ACRO32, demonstra
f) Sorafenib could also block the survival effect of NRTN and combined GDNF+NRTN. g) Sor
transfected in the non-RET-expressing rat pituitary somatotroph cell line GH4C1. (n.d. = not
the absence of GDNF-) (*, p b 0·05; **, p b 0·01; ***, p b 0·001; ****, p b 0·0001).PIT1 andARF levels, and thiswasprevented in the presence of Sorafenib.
In parallel, serum deprivation induced p53 accumulation which was
blocked by GDNF. Sorafenib led to recovery of p53 protein levels and
to apoptosis (Fig. 3).
4. Discussion
The data from this molecular study of sporadic acromegaly tumors
demonstrate that expression of elements of the RET pathway are hall-
marks of acromegaly. GDNF, in particular, is strongly enriched in ACRO
compared with normal pituitary and NFPA. The two RET isoforms
RETL and RETS are equally expressed within ACRO. GFRA1 is the main
co-receptor expressed in ACRO, followed by GFRA4. NRTN is also
expressed in some ACRO. Correlations among expression of various li-
gands and RET indicate redundancy of the RET survival pathway that
completely inhibits the RET apoptotic pathway. Pre-treatment of the
samples with fgSSA reduces expression of PIT1 and GH but do not
alter particularly other genes of the RET pathway.
The most striking result of our work is that ARFmRNA expression is
a sensitive and speciﬁc marker of good prognosis. High ARF levels guar-
antee response while low ARF predict resistance to ﬁrst-line therapy
(surgery plus adjuvant therapy with fgSSA). ARF predictive ability is
not altered in samples from patients submitted to pre-surgery therapy
with fgSSA. The conﬁdence level reaches 100% if GNAS mutation is
used to slightly adjust the cutoff (≥0·1 for non-mutated GNAS and ≥
0·06 for mutated GNAS). This cutoff was initially obtained using TBP
as the control gene to adjust for overall expression, and could also be ob-
tained using another control gene such as ACTB. We also obtained re-
sults at the protein level in tissues from tumors that fully corroborated
the mRNA level data.
mRNA expression is directly related to protein expression for ARF
since it is an mRNA isoform of the CDKN2A gene, that also encodes
p16INK4 [41]. The two isoforms have different promoters and exon 1;
exons 2 and 3 are shared but with different reading frames of transla-
tion, giving rise to two different proteins [41,42]. Initial studies pro-
posed ARF as a marker of good prognosis in cancer [43], although this
idea was subsequently discarded as aggressive cancers either mutate
p53, becoming independent of ARF, or methylate the ARF promoter
[43]. However, whole genome sequencing has repeatedly shown, that
somatotropinomas are benign adenomas with non-mutated p53 (as
well as RET and ARF) [44–47].Moreover, mouse and cell culturemodels
have demonstrated an essential role for ARF and p53 in the regulation of
pituitary cellularity [48,49]. Furthermore, inhibitors of the interaction
between MDM2 and p53, which degrades p53, induces senescence in
pituitary adenomas [50].
Current acromegaly treatment takes a trial-and-error approach:
[51,52] ﬁrst surgery is followed by evaluation at 4–16 weeks, and a
trialwith fgSSA is evaluated after 6–12months. After that, 20–25%of pa-
tients (as in our series) undergo expensive second-line SSA therapy to
which they are also frequently resistant while the peripheral disease
continues unabated due to high GH/IGF1 levels and continued tumor
growth. Risk factors related to a poor prognosis are age and male sex,
size and volume of the adenoma, Knosp grade and extent of invasionib as a potential new treatment. a) Acromegaly (P-ACRO28, P-ACRO30 and P-ACRO32) and
A expression of key genes from Fig. 1: in ACRO, GH, PIT1, GHRHR, RETL and RETS isoforms,
performed by splitting the culture in two (shown by small ‘p’). b) Left: Human GH (hGH)
uantitative hGH (pg/mL) measurements performed in whole medium taken just before
ls (3–4 days). c) Human GDNF (hGDNF) was secreted into the medium by ACRO, but not
32. d) When cells were deprived of GDNF, RET processing induced apoptosis (white bar)
ndocrine tumors (Vandetanib (V), Lenvatinib (L), Sunitinib (Su), Cabozantinib (C) and
trations. Three independent cultures are shown: P-ACRO28, P-ACRO30 and P-ACRO32.
bars) but did not have a strong effect on GDNF-induced survival (black hatched bars).
without exacerbating RET apoptosis in the absence of GDNF (which we assumed to be a
ting a GDNF-counteracting effect at lower doses than those used in cancer treatment.
afenib could block the survival effect of GDNF on both human RETL and RETS isoforms,
detected). (d-g: Mean ± SEM. ANOVA test, all bars compared to white bar –deprived in
Fig. 4. Blocking of RET signal transduction by Sorafenib exchanged the RET-GDNF survival pathway for the RET apoptotic pathway. a) Antibody array performed with extracts from P-
ACRO30 and P-ACRO32 following one- hour incubations in each of four conditions: deprivation (no GDNF), GDNF (500 ng/mL), Sorafenib (4 microg/mL) or Sorafenib+GDNF. b) Signal
quantiﬁcation (Mean ± SEM. ANOVA test): GDNF induced AKT/MTOR phosphorylation, and downregulated active p-p53 (Ser15 p-p53), as well as cleaved PARP (cl-PARP) and
Caspase-3 (cl-CASP3), hallmarks of apoptosis. Sorafenib blocked the AKT pathway, inducing phosphorylation of AMPK, p53 and apoptotic markers. c-e) Western blots with different
cell extracts conﬁrmed the results of the array. c) At 1 h in membrane extracts, GDNF induced full-length RET phosphorylation and blocked Caspase-3 cleavage; both were prevented
by Sorafenib. d) At 1 h in cytoplasmic extracts, GDNF phosphorylated AKT, mTOR and, less intensely, S6K while preventing p53 phosphorylation. In the presence of Sorafenib, GDNF
was unable to activate the AKT/MTOR pathway, but induced phosphorylation of AMPK and p53. As expected, the caspase-processed cytoplasmic fragment of RET (IC-RET) was
strongly expressed in deprived cells in the absence of GDNF, reduced in the presence of GDNF and recovered with Sorafenib. e) In cells deprived of GDNF for 24 h, PIT1 was induced,
activating ARF expression and p53 accumulation, thus leading to apoptosis. GDNF reduced PIT1, ARF and p53 expression, all of which recovered in the presence of Sorafenib. (*, p b
0·05; **, p b 0·01; ***, p b 0·001).
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is curative without causing hypopituitarism than to the biology of the
tumor per se: a larger tumor impinges on and invades surrounding
structures, making surgery less likely to be successful. Importantly,
however, not all the macroadenomas or invasive tumors are resistant
to therapy. Thus, none of these factors, nor the combination of them,
can predict with precision the response to adjuvant fgSSA therapy or
to combined ﬁrst-line treatment.
Several molecular factors have been proposed for early identiﬁcation,
at the time of initial surgery, of SSA-resistant tumors. SSTR2 receptor ex-
pressionhas been themostwidely studied, using immunohistochemistry
and mRNA expression, as it mediates SSA action on somatotroph cells[53–58]. SSTR2 protein expression is correlated with a response to SSA.
However, while the predictive negative value is remarkable, there is no
clear cutoff for SSTR2 expression levels to separate resistant fromrespon-
sive tumors, bothbecause levels canbeaffectedbypre-surgical treatment
and resistance might be mediated by a post-receptor mechanism. This is
also seen in our current series in relation to SSTR2 expressionwhich does
not discriminate between Responsive and Resistant’. Although tumor
granulation (positiveness for CAM5.2) is also related to increased expres-
sion of SSTR2 pre-surgical treatment and other factors affect its immuno-
staining too much for it to be a clear marker.
Other proposed molecular markers include SSTR5, the other
SSA receptor expressed in somatotrophs, dopamine receptors or a
550 M. Chenlo et al. / EBioMedicine 43 (2019) 537–552combination of the two [59,60], and non-receptor proteins such as
ZAC1, E-cadherin, B-arrestin, AIP and Ki67 [61–65]. However, none of
these have reached the consistency or sensitivity of a reliable prognostic
marker [5]. Regarding the newmarker, we propose here, while ARF ap-
pears to have potential as a marker from the current series, ultimately
this will also depend on other prospective studies in more series.
The early identiﬁcation of SSA-resistant patients will also inform the
search for other anti-ACRO pharmacological therapies. In the current
study, we have explored the possibility that TKIs, already used to treat
endocrine cancers, might have an effect against the RET/GDNF/survival
pathway and could be useful in acromegaly. To that end, we have devel-
oped a new culture system, adapted from a previous study of human
thyroid tumors [23] that has enabled us to amplify the number of ade-
noma cells and perform functional and signaling experiments in ACRO
cultures while maintaining the cellular phenotype. Importantly, TKIs
were tested at relevant concentrations with respect to serum levels in
patients. Of the TKIs tested, only Sorafenib was able to inhibit the sur-
vival action of GDNF through RET tyrosine kinase activation without af-
fecting the normal RET/PIT1/ARF/p53 apoptotic pathway in the absence
of GDNF. Lenvatibib, Cabozantinib, Sunitinib and Vandetanib seemed to
affect both apoptosis and survival pathways, and thus to have no net ef-
fect. It could be that these four TKIs are affecting kinases required by the
RET/apoptotic pathway, such as PKCdelta or JNK, which phosphorylates
and recruits CREB and c/EBPa, permanently activating the PIT1 pro-
moter and leading to apoptosis [15]. Sorafenib, on the other hand, had
a dose-response effect and seemed sufﬁciently potent against GDNF to
function at lower doses than those required in cancer therapy. In our
in vitro studies, we have used half the concentration of that found in
serum of the patients in Phase III studies since a relevant percentage
of patients needed a dose reduction due to adverse effects (Supplemen-
tary table 4). Moreover, the dose-response curve indicated that even
lower doses were effective. In any case, if the treatment were effective
for acromegaly, inducing apoptosis, it may be expected a limited treat-
ment for a period of time until resumption or reduction of the adenoma.
As mentioned previously, NRTN is also able to activate RET through
the GFRA1 co-receptor [33–36], and some ACRO also express NRTN.
However, Sorafenib not only blocks the survival action of GDNF but
also that of NRTN and the combination GDNF+NRTN present in some
tumors. Finally, both RET isoforms, RET-L and RET-S, were expressed
in both ACRO tumors and cultures. Sorafenib was also able to block sur-
vival without affecting apoptosis in rat pituitary cells transfected specif-
ically with RETL or RETS.
At the molecular level, Sorafenib was able to directly (after a one-
hour treatment) inhibit GDNF-induced RET phosphorylation, promot-
ing RET degradation. As a consequence, GDNF-induced AKT and mTOR
phosphorylation were also blocked by Sorafenib. Sorafenib activated
AMPKa kinase, which has previously been demonstrated to be by the di-
rect action of Sorafenib on mitochondria by which it reduces the ATP/
AMP quotient [66].However, in the ACRO cultures Sorafenib AMPKa ac-
tivation was potentiated in the presence of GDNF, suggesting that the
mTOR blockade might be involved. AMPKa activation has previously
been proposed as essential for Sorafenib activity [67]. AMPKa activation
is also implicated in cellular autophagy, although it is not clear whether
Sorafenib's anti-tumor activity is necessarily mediated by autophagy
[68]. The possibility remains that other AKT/mTOR related survival
pathways inhibited by Sorafenib could play important roles. The overall
consequence of AMPKa activation or AKT/mTOR inhibition or both was
Caspase-3 activationwith RET processing obtaining the cytopkasmic IC-
RET fragment, an accumulation of PIT1, ARF and p53, and apoptosis, de-
spite the presence of GDNF.
Other data that could be of interest in the future included expression
of PROP1 in ACRO and the role of the GFRA4 co-receptor. PROP1 is a
transcription factor characteristic of embryonic pituitary progenitors
and maintained in postnatal pituitary stem cells [69,70]. During differ-
entiation, PROP1 activates PIT1 while itself being repressed [38,70]. In
ACRO, GDNF was negatively correlated with PIT1, but positively withPROP1 expression, suggesting a role for GDNF in inducing a more
progenitor-like/less differentiated phenotype in adenoma somatotroph
cells. Previous studies in the mouse have demonstrated that three dif-
ferent Gfra4 isoforms expressing GPI, soluble or transmembrane pro-
teins are present in the thyroid and pituitary [40]. Only the Gfra4 GPI
and soluble isoforms, and not the transmembrane isoform, are able to
act as RET co-receptors [71]. Our results in ACRO, measuring total
GFRA4 mRNA and detecting speciﬁc protein isoforms, suggest that the
GFRA4 GPI isoform speciﬁcally is associated with resistance to adjuvant
SSA therapy in acromegaly. Future studies should be performed to as-
sess this speciﬁc isoform. Also for future work is the relations between
the Somatostatin pathway, repressing PIT1 and GH expression, and
the RET pathway including its ligands. Although we did not ﬁnd signif-
icant differences in the pre-surgery therapy group of samples, some cor-
relations with NRTN were lost. But this was a small sample size of pre-
surgically treated samples and future studies will require collecting a
larger number of samples.
In summary, we propose that tumor ARF mRNA expression mea-
sured at the time of the surgery is a prognosis factor in acromegaly,
and that a new pharmacotherapy with Sorafenib could be effective.
Other candidate pharmacological agents are the very speciﬁc anti-RET
TKIs, LOXO-292 and BLU-667, currently undergoing phase I/II and
phase I clinical trials, respectively, for the treatment of neuroendocrine
cancers and potentially applicable to acromegaly in the future. Although
the current series will require validationwith other series, our study in-
cluded 32 ACRO cases of three different hospitals, was prospective and
analysed fresh tissue obtained at initial surgery. Ultimately, the ability
to identify patients who are resistant to ﬁrst-line therapy and the trial
of new pharmaceuticals should improve outcomes in acromegaly.
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